Sunovion Pharmaceuticals Inc.
84 Waterford Drive
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
325 articles with Sunovion Pharmaceuticals Inc.
Sunovion Announces the Commercial Launch of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that KYNMOBI™ (apomorphine HCI) sublingual film is now available in the U.S. by prescription for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). KYNMO
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2020 Certified Customer Service Pro
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.
7/13/2020Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
Sunovion Pharmaceuticals Inc. (Sunovion) today announced topline results from study SEP380-201 , a global, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199, an investigational oral medicine for the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression). SEP-4199 is
Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd. The co-promotion agreement will enable
AMSA and Sunovion Team Up For Second Year of Neuroscience Peer Teaching Program While Transitioning to Remote Learning Experience
The Advanced Math & Science Academy Charter School (AMSA) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced completion of the second year of a program to help students understand Science, Technology, Engineering and Math (STEM) life science career paths within a pharmaceutical company and foster a deeper knowledge of neuroscience. Six AMSA upper school level students, five seniors and one junior, we
Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes
Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes - MISSISSAUGA, Ontario--( BUSINESS WIRE )-- Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI™ (apomorphine HCI) soluble film for the acute, inter
“Today’s approval of Kynmobi advances treatment options for people with Parkinson’s disease who experience OFF episodes and the associated disruption of everyday activities,” said Antony Loebel, Sunovion’s president and chief executive officer.
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD). While Sunovion considers dasotraline to be a promising, novel treatment for BED and ADHD, we believe t
Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.
4/20/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD), which was resubmitted on November 21, 2019.
Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from study SEP361-202 which evaluated the long-term safety and effectiveness of SEP-363856, a novel non-dopamine 2 (D2) agent under investigation for the treatment of patients with schizophrenia.
Sunovion Pharmaceuticals Inc. (Sunovion) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD) in response to the January 29, 2019 Complete Response Letter (CRL).
The award was presented to Dr. Loebel by Dr. Amir Kalali, Chairman and Chief Curator of CNS Summit.
Two Compounds Discovered Using PsychoGenics’ SmartCube® Platform Have Entered Clinical Development
Sunovion’s support services program is recognized by J.D. Power for providing an outstanding customer service experience
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
Sunovion Pharmaceuticals Inc. and PsychoGenics Inc. announced the initiation of the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for SEP-363856, a novel agent for the treatment of adults and adolescents with schizophrenia.